Raymond James Trust N.A. increased its stake in HealthEquity by 4.8%, owning 2,905 shares valued at $238,000, while Citigroup Inc. raised its position by 73.0%, holding 102,107 shares worth $8,357,000. Institutional investors control 99.55% of the stock, which has a current consensus rating of "Moderate Buy" and a target price of $113.69. KeyCorp has lowered its price target for HealthEquity from $120.00 to $110.00, indicating a potential upside of 29.59%.